ARTCLINE announces closing of €5 million financing

ARTCLINE announces closing of €5 million financing

• ARTCLINE GmbH successfully closes €5 million convertible loan
• Financing secures full recruitment and evaluation of ongoing ReActIF-ICE clinical trial
• Webinar with operational and strategic update announced for 29 September 2025

Rostock, Germany, September 9, 2025 – ARTCLINE, a biomedical company focused on the development of novel immune cell therapies for the treatment of septic shock, announces the successful closing of a €5 million financing round. The financing via a convertible loan was carried out with strong support from existing as well as new investors.

The funds will be used to complete and evaluate the ongoing randomized, controlled multicenter study ReActIF-ICE (NCT05442710), and preparation for market launch. The aim of the study is to validate the clinical benefits of the patented extracorporeal ARTICE^® therapy developed by ARTCLINE for the treatment of immune dysfunction in septic shock.

Dirk Hessel, Managing Director of ARTCLINE GmbH, commented: “We are delighted with the great confidence our investors are placing in ARTCLINE by supporting this crucial phase of the company's development. This financing secures the finalization and evaluation of the ReActIF-ICE study, which is expected to be completed in the first quarter of 2026. The results of this important study, addressing a highly complex indication with significant unmet medical need, are eagerly awaited by the medical community, patients, and their families.”

Jens Altrichter, MD, Managing Director and founder of ARTCLINE GmbH, added: “Sepsis is one of the leading causes of death worldwide, accounting for one in five fatalities. While patients may survive the initial phase of septic shock, the subsequent immune dysfunction often leads to fatal secondary infections or organ failure. This is exactly where the ARTICE^® therapy is administered: it uses immune cells from healthy donors to support and regenerate the impaired immune system of patients with septic shock, giving ARTCLINE a unique position compared to the therapy options currently available.”

Webinar announcement

On 29 September 2025, ARTCLINE will host a webinar for interested investors and members of the press, showcasing the ARTICE^® therapy procedure in the context of modern treatments for septic shock. In addition, the treatment approach, the current progress of the ongoing ReActIF-ICE clinical trial, the status of corporate financing and the strategic outlook will be presented.

About ARTCLINE GmbH

ARTCLINE GmbH is developing innovative therapeutic approaches for intensive care medicine. The company focuses on a novel, immune cell-based extracorporeal therapy for the treatment of septic shock – one of the major challenges for global health systems.
The ARTICE^® therapy, developed in collaboration between immunologists and dialysis specialists, uses allogeneic immune cells from healthy donors to temporarily support key functions of the patient's dysregulated immune system and help restore its activity.
For more information, please visit www.artcline.de, follow us on LinkedIn or contact us at info@artcline.de.

Contact:       
ARTCLINE GmbH     
Dirk Hessel, Managing Director     
dirk.hessel@artcline.de     

Media inquiries:
MC Services AG
Eva Bauer / Julia von Hummel
Phone: +49-89-210228-0
artcline@mc-services.eu